Apexian Pharmaceuticals is Closing a Series A Round to Initiate Phase 1 Trial

Indianapolis, IN – November 29, 2017 – Apexian Pharmaceuticals, an Indiana-based clinical stage biotechnology company developing novel compounds to treat cancer, announced today that they are closing their Series A round. This financing follows previous investments as well as numerous grants and awards by the company since its founding. Proceeds will be used to initiate their phase 1 clinical study for APX3330 a novel first … Read more…

Apexian Pharmaceuticals to participate in the National Cancer Institute’s SBIR Investor Initiatives program

Indianapolis-based Apexian Pharmaceuticals, a clinical-stage biotech company developing novel compounds to treat cancer by leveraging intellectual property discovered at the Indiana University School of Medicine has been selected to participate in the National Cancer Institute’s SBIR Investor Initiatives program. As part of the program, Dr. Richard Messmann — Apexian’s chief medical officer — will present at the BioNetwork Partnering Summit taking place Oct. 23-25 in … Read more…